Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?

Executive Summary

The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer

You may also be interested in...

Pfizer False Claims Act Ruling Keeps High Evidentiary Standards, Limits Employee Protections

Appeals court rules that aggregate data of government expenditures are not a substitute evidence of actual false claims and that FCA does protect whistleblowers who just report regulatory violations.

Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads

Pfizer, which co-markets the Alzheimer's treatment with Eisai, could feel the biggest impact of the notice of violation due to its settlement with state attorneys general.

Lessons From The Pfizer Off-Label Settlement: Compliance Programs Not Enough To Demonstrate Integrity, DOJ Says

A lesson of Pfizer's $2.3 billion corporate integrity settlement with the Department of Justice is that good integrity policies are meaningless without employee adherence, according to government attorneys

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts